PLATINEA 2.0 Availability and individualized use of antibiotics
| Reference number | |
| Coordinator | Uppsala universitet - Uppsala universitet Inst f medicinska vetenskaper |
| Funding from Vinnova | SEK 39 821 515 |
| Project duration | October 2021 - September 2026 |
| Status | Ongoing |
| Venture | Innovation milieus in precision health |
| Call | Innovation milieus in precision Health 2021 |
Purpose and goal
Optimised use of antibiotics (substance, dose, duration) and individualised therapy for infectious diseases are needed to achieve clinical cure, while reducing the risks of side effects and emergence of resistant bacteria. Sustainable access to a wide arsenal of antibiotics is prerequisite for precision medicine. PLATINEA´s vision is to create intersectoral innovation hub that that operates together with many national and international actors to complement ongoing initiatives, and promote rational antibiotic use tailored to each individual patient.
Expected results and effects
PLATINEA identifies and proposes actions to ensure sustainable access to antibiotics and contributes to the assessment of medically important knowledge gaps. The project includes studies aiming to optimise use of antibiotics, as well as national implementation of methods to promote rational use in patient care. Expected benefits of the project include more effective treatment of infections, prevention of emergence of resistance and reduced costs for health care. The innovation hub strengthens Sweden´s leading position in the field of antibiotics and antibiotic resistance.
Planned approach and implementation
PLATINEA includes multiple actors representing different sectors (health care, universities, authorities, and industry) thereby facilitating communication and coordination of activities between stakeholders. The project includes several types of activities that are all needed to support individualised treatment of bacterial infections inventory of knowledge gaps, optimisation studies, implementation in patient care, availability of a broad panel of antibiotics and identification of patients at risk of severe disease, resistant bacteria, and complications.